Released Aug 6, 2015, after the close
10-Q filed Aug 10, 2015, 41 days after period end · 0001019687-15-003021
Q2 2015 · 10-Q
Revenue$6.19M$6.19M −9.9% vs Q2 2014+8.2% vs Q1 2015
Net Income-$2.63M-$2.63M N/M vs Q2 2014N/M vs Q1 2015
EPS Diluted-$1.43-$1.43 N/M vs Q2 2014N/M vs Q1 2015
Operating Income-$2,472,000N/M
Operating Cash Flowderived-$2,130,000N/M
Free Cash Flowderived-$2,360,000N/M
Margins · derived
Operating margin-39.9%−21.0 pt vs Q2 2014
Net margin-42.4%−22.8 pt vs Q2 2014
What the release said
The release
Same quarter
| Metric | Q2 2015 | Q2 2014 | Q2 2013 | Q2 2012 |
|---|---|---|---|---|
| Revenue | $6.19M | $6.87M | $5.53M | $6.02K |
| Net Income | -$2.63M | -$1.35M | -$99.00K | -$633.00K |
| EPS Diluted | -$1.43 | -$0.02 | $0.00 | -$0.01 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR